190 related articles for article (PubMed ID: 19458122)
1. The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury.
Huber JM; Tagwerker A; Heininger D; Mayer G; Rosenkranz AR; Eller K
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F451-60. PubMed ID: 19458122
[TBL] [Abstract][Full Text] [Related]
2. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
Schmidt N; Gonzalez E; Visekruna A; Kühl AA; Loddenkemper C; Mollenkopf H; Kaufmann SH; Steinhoff U; Joeris T
Gut; 2010 Jul; 59(7):896-906. PubMed ID: 20581238
[TBL] [Abstract][Full Text] [Related]
3. Loss of clusterin expression worsens renal ischemia-reperfusion injury.
Zhou W; Guan Q; Kwan CC; Chen H; Gleave ME; Nguan CY; Du C
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F568-78. PubMed ID: 20007348
[TBL] [Abstract][Full Text] [Related]
4. The effect of murine anti-thymocyte globulin on experimental kidney warm ischemia-reperfusion injury in mice.
Jang HR; Gandolfo MT; Ko GJ; Racusen L; Rabb H
Transpl Immunol; 2009 Dec; 22(1-2):44-54. PubMed ID: 19682579
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Shimizu K; Sato S
J Leukoc Biol; 2010 Jul; 88(1):117-22. PubMed ID: 20418448
[TBL] [Abstract][Full Text] [Related]
6. P53-Rb signaling pathway is involved in tubular cell senescence in renal ischemia/reperfusion injury.
Kailong L; Du X; Yani H; Lin Z; Jvrong Y; Ruihua S; Lin C
Biocell; 2007 Aug; 31(2):213-23. PubMed ID: 17902269
[TBL] [Abstract][Full Text] [Related]
7. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
Wilck N; Fechner M; Dreger H; Hewing B; Arias A; Meiners S; Baumann G; Stangl V; Stangl K; Ludwig A
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1418-26. PubMed ID: 22516063
[TBL] [Abstract][Full Text] [Related]
9. Expression of SSAT, a novel biomarker of tubular cell damage, increases in kidney ischemia-reperfusion injury.
Zahedi K; Wang Z; Barone S; Prada AE; Kelly CN; Casero RA; Yokota N; Porter CW; Rabb H; Soleimani M
Am J Physiol Renal Physiol; 2003 May; 284(5):F1046-55. PubMed ID: 12554636
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2.
Hwang HS; Yang KJ; Park KC; Choi HS; Kim SH; Hong SY; Jeon BH; Chang YK; Park CW; Kim SY; Lee SJ; Yang CW
Nephrol Dial Transplant; 2013 May; 28(5):1156-66. PubMed ID: 23229926
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
Basler M; Lauer C; Beck U; Groettrup M
J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
[TBL] [Abstract][Full Text] [Related]
12. Netrin-1 regulates Th1/Th2/Th17 cytokine production and inflammation through UNC5B receptor and protects kidney against ischemia-reperfusion injury.
Tadagavadi RK; Wang W; Ramesh G
J Immunol; 2010 Sep; 185(6):3750-8. PubMed ID: 20693423
[TBL] [Abstract][Full Text] [Related]
13. Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib.
Sinn DI; Lee ST; Chu K; Jung KH; Kim EH; Kim JM; Park DK; Song EC; Kim BS; Yoon SS; Kim M; Roh JK
Neurosci Res; 2007 May; 58(1):12-8. PubMed ID: 17328981
[TBL] [Abstract][Full Text] [Related]
14. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
15. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
Duechler M; Linke A; Cebula B; Shehata M; Schwarzmeier JD; Robak T; Smolewski P
Eur J Haematol; 2005 May; 74(5):407-17. PubMed ID: 15813915
[TBL] [Abstract][Full Text] [Related]
16. Role of alpha/beta and gamma/delta T cells in renal ischemia-reperfusion injury.
Hochegger K; Schätz T; Eller P; Tagwerker A; Heininger D; Mayer G; Rosenkranz AR
Am J Physiol Renal Physiol; 2007 Sep; 293(3):F741-7. PubMed ID: 17567936
[TBL] [Abstract][Full Text] [Related]
17. Effect of rapamycin on renal ischemia-reperfusion injury in mice.
Lui SL; Chan KW; Tsang R; Yung S; Lai KN; Chan TM
Transpl Int; 2006 Oct; 19(10):834-9. PubMed ID: 16961776
[TBL] [Abstract][Full Text] [Related]
18. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney.
Awad AS; Ye H; Huang L; Li L; Foss FW; Macdonald TL; Lynch KR; Okusa MD
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1516-24. PubMed ID: 16403835
[TBL] [Abstract][Full Text] [Related]
19. Effects of delayed rapamycin treatment on renal fibrosis and inflammation in experimental ischemia reperfusion injury.
Liu M; Agreda P; Crow M; Racusen L; Rabb H
Transplant Proc; 2009 Dec; 41(10):4065-71. PubMed ID: 20005342
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
